By incorporating Gal ligands to achieve ASGPR-mediated active targeting, this strategy is anticipated to overcome the limitations of existing RSV-delivery strategies and provide a novel paradigm for NAFLD therapy. The gene discussed is GAL; the disease is metabolic dysfunction-associated steatotic liver disease.